Mar 06, 2023 / 06:30PM GMT
Laura Niklason - Humacyte, Inc. - Founder, President, CEO
(audio in progress)
-- doing and what it's going to do in the future. And certainly, if I should gloss over anything too quickly, then we'd be happy to talk with any of the audience participants after the talk.
So this is just our standard disclaimer. So Humacyte is really a first-in-class regenerative medicine technology company. We are the only company in the world that engineers replacement human tissues, basically spare parts for people, in a way that is at commercial scale and in a way that the tissues themselves are universally implantable. They can go into any human recipient without rejection. And that makes us unique in the field of regenerative medicine.
We have received FDA designation of Regenerative Medicine Advanced Therapy, or RMAT designation, as well as a Defense Department priority designation in the last several years. The total markets that Humacyte estimates it can address, the total addressable markets worldwide, are about $150 billion. The reason our total addressable markets are so large is
Humacyte Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers